

# Sofosbuvir plus peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients

April 25 2015

---

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%,  $p = 0.008$ ) or 16 weeks (71%,  $p$

Citation: Sofosbuvir plus peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients (2015, April 25) retrieved 29 June 2024 from <https://medicalxpress.com/news/2015-04-sofosbuvir-peginterferonribavirin-virologic-response-g3.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.